(NASDAQ: BNTC) Benitec Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Benitec Biopharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast BNTC's revenue for 2028 to be $398,339,268, with the lowest BNTC revenue forecast at $120,832,991, and the highest BNTC revenue forecast at $675,845,544. On average, 2 Wall Street analysts forecast BNTC's revenue for 2029 to be $1,936,271,883, with the lowest BNTC revenue forecast at $1,567,756,860, and the highest BNTC revenue forecast at $2,304,786,906.
In 2030, BNTC is forecast to generate $6,312,499,782 in revenue, with the lowest revenue forecast at $3,027,224,833 and the highest revenue forecast at $9,597,774,731.